Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Short interest of 10,043,451 is only 217K less than the all time record high from the previous report.
This factor and days to cover is going to get interesting and it all will happen in a little over 5 weeks or less, that TLD PR could come out any day now.
IR said they would PR the TLD when it becomes available and is not dependent on waiting until the Alzheimer conference where Anavex will be presenting on Dec 1st.
Short interest show very close to 14 business days to cover.
If this amount of short interest holds up until the Alzheimer TLD is PRed, it's going to get highly volatile in the up direction if there is a halt to PR the good to great news as I expect.
MM will be scrambling to find shares to fill the big clients and institutional funds during and after the halts. I expect there will be multiple halts during the day.
Short Interest just out :
SETTLEMENT DATE SHORT INTEREST AVG. DAILY SHARE VOLUME DAYS TO COVER
10/14/2022 ***10,043,451***718,819***13.972156
09/30/2022 ***10,260,594***936,366***10.957888
09/15/2022 ***9,737,900****683,304***14.251197
08/15/2022 ***8,428,105***784,854***10.73843731
07/29/2022 ***8,726,226 ***855,980***10.1944277
07/29/2022 ***8,726,226***855,980***10.1944277
07/15/2022 ***8,260,601***918,653****8.99208
06/30/2022 ***8,707,363 ***1,190,086**7.316583
https://www.nasdaq.com/market-activity/stocks/avxl/short-interest
From ST, by Spectaculator 32min ago
Anavex IR just confirmed - Dr. McFarlane will be the speaker presenting data at CTAD
DD for new eyes: AVXL has a pipeline of multiple trials with some in the late stage; and a portfolio of 4 drugs.
A2-73 Blarcamesine for:
Alzheimer's Disease.
Parkinson's Disease.
Rett Syndrome.
Infantile Spasms.
Fragile X.
Angelman's Syndrome.
Undisclosed Rare disease.
A3-71:
Frontotemporal Dementia (FTD).
Neurodegenterative Disease.
A1-41:
Depression.
Stroke.
Neurodegenterative Disease.
A-1066
Visceral Pain
Acute & Neuropathic Pain.
Source link:
https://www.anavex.com/_files/ugd/79bcf7_3cc5b85e0f1d49bb84e60f933ecbbea8.pdf
"Breakeven On The Horizon For Anavex Life Sciences Corp. (NASDAQ:AVXL) Simply Wall St Tue, October 25, 2022 at 7:22 AM
"Anavex Life Sciences is bordering on breakeven, according to the 4 American Biotechs analysts...... see link
https://finance.yahoo.com/news/breakeven-horizon-anavex-life-sciences-112207058.html
IhidfromtheX, that is really great news, especially "nothing new found".
Looks like you have been blessed.
Mayo, I sent funds last night. I wish you success on your trip, and good luck with the meeting.
mrplmer the real problem is that SAVA's fix is downstream from AVXL's fix upstream, ensuring that the proteins are correctly folded at the S1 receptor site leading into the mitochondria creating the desired homeostasis; making SAVA drug redundant and not needed.
This is not just my opinion but falconer and Mayo have expressed that educated opinion.
Just crossed vol of One Million (MM).
AVXL has an extensive pipeline of current and planned trials and a portfolio of 4 drugs.
A2-73 Blarcamesine for:
Alzheimer's Disease.
Parkinson's Disease.
Rett Syndrome.
Infantile Spasms.
Fragile X.
Angelman's Syndrome.
Undisclosed Rare disease.
A3-71:
Frontotemporal Dementia (FTD).
Neurodegenterative Disease.
A1-41:
Depression.
Stroke.
Neurodegenterative Disease.
A-1066
Visceral Pain
Acute & Neuropathic Pain.
Source link:
https://www.anavex.com/_files/ugd/79bcf7_3cc5b85e0f1d49bb84e60f933ecbbea8.pdf
AVXL Due Diligence and various sources:
Anavex Late-Breaking Presentation of Phase 2b/3 Alzheimer Data
https://finance.yahoo.com/news/anavex-life-sciences-announces-breaking-110000032.html
Update Compendium,
Projected Blarcamesine Revenues & Market Cap. Compiled by Mayo:
https://www.sotcanalytics.com/update-compendium
Jun 2022 Commentary on Anavex's First Educational Video
https://www.anavex.com/vnrjune2022
NEWS: Anavex Announces First Entire Clinical Alzheimer’s Gene Pathway Data of ANAVEX®2-73
https://www.anavex.com/post/anavex-announces-first-entire-clinical-alzheimer-s-gene-pathway-data-of-anavex-2-73-at-aaic-2022
June Corporate Slides.
Anavex programs, trials, graphs, and useful data:
https://www.anavex.com/_files/ugd/850d88_6d847f744209465f82a4ad655bb25941.pdf
Piotrpeterblog.com is an independent analysis blog on Alzheimer and CNS Drugs.
https://piotrpeterblog.com/
An extensive list of topics with links, compiled DD, and recent posts. Compiled by XenaLives
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=166917727
A report given by Dr. Randi Hagerman, a recognized leader WW for CNS conditions and treatments. Compiled by tradeherpete.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=168422630
Anavex Company, an Overview; compiled by Mayo Mobile:
https://drive.google.com/file/d/15i9suShnAjC_Vq5gEl-ocp3ebsWKr0fd/view
Today's Anavex news: "Anavex Life Sciences Announces Late-Breaking Presentation of Phase 2b/3 Data of Oral ANAVEX®2-73 (blarcamesine) for Early Alzheimer’s Disease at the Upcoming Clinical Trials on Alzheimer’s Disease (CTAD) Congress 2022"
Anavex Life Sciences Corp.
Mon, October 17, 2022 at 7:00 AM
NEW YORK, Oct. 17, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) disorders, today announced that the company will present Phase 2b/3 ANAVEX®2-73-AD-004 data of oral ANAVEX®2-73 (blarcamesine) for Early Alzheimer’s Disease at the upcoming Clinical Trials on Alzheimer’s Disease (CTAD) Congress 2022 in San Francisco, CA and publish the findings in a peer-reviewed medical journal.
Top Line Data of ANAVEX®2-73 (blarcamesine) Randomized, Double-blind, Multicenter, Placebo-controlled Phase 2b/3 in Patients with Early Alzheimer’s Disease (AD)
Date / Time: December 1, 2022 / 4:30pm PT
Presenter: A/Prof. Stephen Macfarlane, Principal Investigator
Session Title: LB8 - LATE BREAKING ORAL COMMUNICATIONS
ANAVEX®2-73 (blarcamesine) is an orally available, small-molecule activator of the sigma-1 receptor (SIGMAR1), which, data suggest, is pivotal to restoring neural cell homeostasis and promoting neuroplasticity.1
Prior to the completion of the larger Phase 2b/3 study ANAVEX®2-73-AD-004 (NCT03790709) for the treatment of Early Alzheimer’s Disease, using precision medicine included SIGMAR1 biomarker of response, ANAVEX®2-73 (blarcamesine) successfully completed a randomized, double-blind, multicenter, placebo-controlled Phase 2 in Parkinson’s disease dementia and a Phase 2a clinical trial for Alzheimer’s disease. In addition, ANAVEX®2-73 (blarcamesine) successfully completed a randomized, double-blind, multicenter, placebo-controlled Phase 2 in adult Rett syndrome and a randomized, double-blind, multicenter, placebo-controlled Phase 3 in adult Rett syndrome, respectively.
Volume 1.1 Million (MM).
For new eyes DD:
AVXL pipeline of trials and drugs:
A2-73 Blarcamesine for:
Alzheimer's Disease.
Parkinson's Disease.
Rett Syndrome.
Infantile Spasms.
Fragile X.
Angelman's Syndrome.
Undisclosed Rare disease.
A3-71:
Frontotemporal Dementia (FTD).
Neurodegenterative Disease.
A1-41:
Depression.
Stroke.
Neurodegenterative Disease.
A-1066
Visceral Pain
Acute & Neuropathic Pain.
Source link:
https://www.anavex.com/_files/ugd/79bcf7_3cc5b85e0f1d49bb84e60f933ecbbea8.pdf
AVXL Due Diligence for new eyes and reference material for old eyes - 9 Sources:
AVXL Alzheimer Ph-2b/3 'Top Line Data' release at CTAD Nov 29- Dec 2, 2022
https://www.ctad-alzheimer.com/
Update Compendium, a 3rd party independent review and projections with data and sources.
Projected Blarcamesine Revenues & Market Cap; plus a wealth of other data and important details. Compiled by Mayo:
https://www.sotcanalytics.com/update-compendium
Jun 2022 Commentary on Anavex's First Educational Video.
A report from various members of the company management team on current operations and future projections:
https://www.anavex.com/vnrjune2022
NEWS: Anavex Announces First Entire Clinical Alzheimer’s Gene Pathway Data of ANAVEX®2-73 at AAIC 2022
https://www.anavex.com/post/anavex-announces-first-entire-clinical-alzheimer-s-gene-pathway-data-of-anavex-2-73-at-aaic-2022
June Corporate Slides.
Very useful for a visual look at all the Anavex programs, trials, graphs, and useful data:
https://www.anavex.com/_files/ugd/850d88_6d847f744209465f82a4ad655bb25941.pdf
Piotrpeterblog.com is an independent analysis blog on Alzheimer and CNS Drugs.
https://piotrpeterblog.com/
An extensive list of a wide range of various topics with links, compiled DD, and recent posts. Compiled by XenaLives
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=166917727
A report given by Dr. Randi Hagerman, a recognized leader WW for CNS conditions and treatments. Compiled by tradeherpete.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=168422630
Anavex Company, an Overview; compiled by Mayo Mobile:
https://drive.google.com/file/d/15i9suShnAjC_Vq5gEl-ocp3ebsWKr0fd/view
Good luck with the DD, feel free to ask the knowledgeable board any questions.
RedShoulder
I think the Alzheimer TLD will be PRed after the stock is halted for the news.
I believe the data will show a significant amount of the patients improved and some maintained during the trial. No AD drug except A2-73 Blarcamesine has achieved that as they did in the Ph-2 trial.
It will be quite the 'gapper' when trading resumes.
Look at the instant Billions in MC increase that Biogen did with a drug that only slows down the AD disease a bit.
It's going to be glorious.
I've been away all day and just got in, to say I was surprised would be an understatement.
This looks like they have good to excellent data by the line up, or some of those would have declined.
AD) Stephen Macfarlane 1, Timo Grimmer 2, Terence O’brien 3, Edward Hammond 4, Walter Kaufmann 4, Emmanuel Fadiran 4, Christopher Missling 4 1Hammoncare - Melbourne (Australia), 2THU Munich - Munich (Germany), 3Monash University, Alfred Health - Melbourne (Australia), 4Anavex Life
Many thanks TTT, you are quick on the draw and usually find the good stuff first.
https://www.ctad-alzheimer.com/final-program
Short interest is out and it is a record high.
SETTLEMENT DATE SHORT INTEREST AVG. DAILY SHARE VOLUME DAYS TO COVER
09/30/2022**10,260,594**936,366**10.957888
09/15/2022***9,737,900***683,304 ***14.251197
08/31/2022***9,102,975***706,411***12.886231
08/15/2022***8,428,105***784,854***10.738437
07/29/2022***8,726,226***855,980 ***10.194427
07/15/2022***8,260,601***918,653***8.99208
This will work out to an advantage if the AD TLD news is on a 'Halt', with more covering buys required.
$11.01 just printed on fairly low vol. It must be fall.
12x thanks for clearing up some misconceptions about the PDD trial data.
Your well detailed post is worth a second read:
The bottom line is that no drug has ever improved or stopped the decline of Alzheimer, except A2-73 Blarcamesine in the Ph-2 trial. There are several YouTubes where those patients were interviewed years after starting the trial showing a recovery from the disease.
Look at the increase of Billions in Market Cap for the recent release of Biogen data that only slowed down the disease, the disease continued only at a slower rate down hill. I am expecting AVXL to explode the MC Billions higher once the data is released.
I expect that the coming AD TLD release will show some have started the recovery and some did not decline.
Don't let FUD talk you into selling before the news.
We will not have to wait long to see the results.
Lol, I have a problem sometimes with conforming if the message is the same.
However no sweat; I'll go with SMA in the future.
Thanks Zena, I was meaning 200 Day MA.